We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Neurocrine Biosciences Inc | LSE:0K6R | London | Ordinary Share | NEUROCRINE BIOSCIENCES ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 91.67 | 3,049 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.89B | 249.7M | 2.5414 | 49.13 | 9.01B |
TIDMDNL TIDMTTM
RNS Number : 2423Y
Stifel Nicolaus Europe Limited
05 September 2022
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION (a) Name of exempt principal trader: Stifel Nicolaus Europe Limited (b) Name of offeror/offeree in relation to whose relevant securities this form Diurnal Group plc relates: Use a separate form for each offeror/offeree ------------------------------- (c) Name of the party to the offer with which exempt principal trader is connected: Diurnal Group plc ------------------------------- (d) Date dealing undertaken: 02 September 2022 ------------------------------- (e) In addition to the company in 1(b) above, is the exempt principal trader making N/A disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A" ------------------------------- 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales Class of relevant Purchases/ sales Total number of Highest price per unit Lowest price per unit security securities paid/received paid/received Ordinary Buy 16,855 26.77 GBx 26.705 GBx ----------------- ------------------------ ----------------------- ----------------------- (b) Cash-settled derivative transactions Class of relevant Product description Nature of dealing Number of reference Price per unit security e.g. CFD e.g. opening/closing a securities long/short position, increasing/reducing a long/short position (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, Number of Exercise Type Expiry date Option money relevant description purchasing, securities price per e.g. paid/ security e.g. call selling, to which unit American, received per option varying etc. option European unit relates etc. (ii) Exercise Class of relevant Product description Exercising/ exercised Number of securities Exercise price per security e.g. call option against unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing Details Price per unit (if applicable) e.g. subscription, conversion 3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" Date of disclosure: 05 September 2022 Contact name: Vijay Odedra ------------------ Telephone number: 02077107621 ------------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FERDZGGLVKKGZZG
(END) Dow Jones Newswires
September 05, 2022 07:00 ET (11:00 GMT)
1 Year Neurocrine Biosciences Chart |
1 Month Neurocrine Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions